NASDAQ NMS - GLOBAL MARKET · CGON
+2.95% · +$2.29 · Vol 701.9K
Market closed · last close 4:00 PM ET · price as of 18:35:44 ET
CG Oncology Inc

CG Oncology Inc

Biotechnology
$79.90
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Earnings absence reason unknown · Analyst data unavailable at compute time
CGON
CG Oncology Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
SELL BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

42/ 100
Veridion Score
SELL BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is CGON moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading CGON catalysts
About CG Oncology Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2024
Employees
142
Country
US

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$78.69
Day high
$79.89
Day low
$77.38
Previous close
$77.61
52W high
$80.68
-0.97% from high
52W low
$25.42
99% of range
Market cap
$7.1B
EPS
$-2.7200
Beta
1.04
Shares out
88.6M
Volume
701.9K
0.82× rel vol
Avg volume
851.9K
VWAP
$79.33
Price history computed in-house
1W
+3.62%
1M
+15.26%
3M
+29.10%
1Y
+196.86%
YTD
+92.44%
SMA 50 $71.03 · above
SMA 200 $59.26 · above
52W position 99%

CGON overview

Veridion Score
42
Registered · 2026-08-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around CGON.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading CGON Form 4 filings
Public disclosures

Congress activity in CGON

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for CGON in the cached public ledger.

Federal contracts

CGON contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CGON in this window.
Lobbying spend

CGON lobbying filings, year to date.

Registered lobbying filings matched to CG Oncology Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CGON in this window.
Loading news for CGON
Analyst ratings
Sovereign unlock shows live analyst consensus for CGON.
Options
Sovereign unlock shows live options positioning for CGON.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.